The 80mg dose hasn't been proven in Japan so I cant see fast tracking.
Plus the fact the flu market is sufficiently covered by existing drugs.
There's no major imperative for the FDA to fast track. They probably don't care BARDA is blowing its budget allocations replicating trials.